Diuretics    O
-    O
furosemide    O
,    O
chlorthalidone    B-SulfaDrug104352070
,    O
butamide    O
,    O
triamterene    O
/    O
hydrochlorothiazide    O

Atenolol    O
/    O
chlorthalidone    O
(    O
brand    O
name    O
Tenoretic    O
)    O
is    O
a    O
combination    O
of    O
two    O
drugs    O
prescribed    O
for    O
hypertension    O
:    O
atenolol    O
and    O
chlorthalidone    B-SulfaDrug104352070
.    O

Co    O
-    O
tenidone    O
(    O
BAN    O
)    O
is    O
a    O
non    O
-    O
proprietary    O
name    O
used    O
to    O
denote    O
a    O
combination    O
of    O
atenolol    O
and    O
chlortalidone    B-SulfaDrug104352070
.    O

Bleaching    O
resistance    O
–    O
The    O
line    O
shall    O
remain    O
visible    O
when    O
tested    O
with    O
an    O
aqueous    O
3    O
%    O
freshly    O
made    O
solution    O
of    O
chloramine-T    B-SulfaDrug104352070
(    O
mass    O
fraction    O
)    O
.    O

The    O
niacin    O
test    O
strip    O
is    O
typically    O
composed    O
of    O
potassium    O
thiocyanate    O
,    O
chloramine-T    B-SulfaDrug104352070
,    O
citric    O
acid    O
,    O
and    O
4-Aminosalicylic    O
acid    O
.    O

:    O
N05AL07    O
Levosulpiride    B-SulfaDrug104352070

ersentilide    B-SulfaDrug104352070
(    O
INN    O
)    O

cyclothiazide    B-SulfaDrug104352070
,    O
a    O
positive    O
allosteric    O
modulator    O
of    O
the    O
AMPA    O
receptor    O

Cyclothiazide    B-SulfaDrug104352070
:    O
non    O
-    O
selective    O
non    O
-    O
competitive    O
antagonist    O

Sulfoaildenafil    B-SulfaDrug104352070

diclofenamide    B-SulfaDrug104352070
(    O
INN    O
)    O

SB-271,046    B-SulfaDrug104352070

Argatroban    B-SulfaDrug104352070
is    O
an    O
anticoagulant    O
that    O
is    O
a    O
small    O
molecule    O
direct    O
thrombin    O
inhibitor    O
.    O

Others    O
oprelvekin    O
,    O
romiplostim    O
,    O
eltrombopag    O
,    O
argatroban    B-SulfaDrug104352070

Previously    O
known    O
venomous    O
squamates    O
have    O
already    O
provided    O
the    O
basis    O
for    O
medications    O
such    O
as    O
Ancrod    O
,    O
Captopril    O
,    O
Eptifibatide    O
,    O
Exenatide    O
and    O
Tirofiban    B-SulfaDrug104352070
.    O

tirofiban    B-SulfaDrug104352070

They    O
are    O
available    O
as    O
eye    O
drops    O
(    O
Trusopt    O
and    O
Azopt    O
)    O
and    O
pills    O
(    O
Diamox    B-SulfaDrug104352070
and    O
Neptazane    B-SulfaDrug104352070
)    O
.    O

Veralipride    B-SulfaDrug104352070
(    O
Agreal    B-SulfaDrug104352070
,    O
Agradil    B-SulfaDrug104352070
)    O
is    O
a    O
benzamide    O
neuroleptic    O
medicine    O
indicated    O
in    O
the    O
treatment    O
of    O
vasomotor    O
symptoms    O
associated    O
with    O
the    O
menopause    O
.    O

SU6656    B-SulfaDrug104352070
is    O
a    O
Src    O
family    O
kinase    O
inhibitor    O
developed    O
by    O
the    O
biotechnology    O
company    O
SUGEN    O
Inc    O
(    O
a    O
subsidiary    O
of    O
Pharmacia    O
)    O
in    O
2000    O
.    O

Simeprevir    B-SulfaDrug104352070
,    O
sold    O
under    O
the    O
trade    O
names    O
Olysio    B-SulfaDrug104352070
among    O
others    O
,    O
is    O
a    O
medication    O
used    O
in    O
combination    O
with    O
other    O
medications    O
for    O
the    O
treatment    O
of    O
hepatitis    O
C.    O
It    O
is    O
specifically    O
used    O
for    O
hepatitis    O
C    O
genotype    O
1    O
and    O
4    O
.    O

Simeprevir    B-SulfaDrug104352070
(    O
TMC435    O
,    O
tradename    O
Olysio    O
)    O
,    O
an    O
HCV    O
NS3/4A    O
protease    O
inhibitor    O
for    O
treatment    O
of    O
chronic    O
hepatitis    O
C    O
in    O
combination    O
with    O
pegylated    O
interferon    O
/    O
ribavirin    O
or    O
with    O
other    O
direct    O
-    O
acting    O
anti    O
-    O
HCV    O
agents    O
.    O

SB-399,885    B-SulfaDrug104352070

Cimicoxib    B-SulfaDrug104352070

Third    O
generation    O
drugs    O
include    O
glimepiride    B-SulfaDrug104352070
,    O
although    O
it    O
is    O
sometimes    O
considered    O
second    O
-    O
generation    O
,    O
while    O
others    O
classify    O
it    O
as    O
third    O
-    O
generation    O
sulfonylurea    O
.    O

image    O
:    O
Glimepiride    B-SulfaDrug104352070
(    O
2nd    O
generation    O
)    O

:*    O
Glimepirid    O
Orion    O
(    O
"    O
glimepiride    B-SulfaDrug104352070
"    O
)    O

Naluzotan    B-SulfaDrug104352070
—    O
antidepressant    O

Saridegib    B-SulfaDrug104352070
,    O
also    O
known    O
as    O
IPI-926    B-SulfaDrug104352070
,    O
is    O
an    O
experimental    O
drug    O
candidate    O
undergoing    O
clinical    O
trials    O
for    O
the    O
treatment    O
of    O
various    O
types    O
of    O
cancer    O
,    O
including    O
hard    O
-    O
to    O
-    O
treat    O
hematologic    O
malignancies    O
such    O
as    O
myelofibrosis    O
and    O
ligand    O
-    O
dependent    O
tumors    O
such    O
as    O
chondrosarcoma    O
.    O

mefruside    B-SulfaDrug104352070
(    O
INN    O
)    O

Naratriptan    B-SulfaDrug104352070

Naratriptan    B-SulfaDrug104352070

IFIS    O
has    O
been    O
associated    O
with    O
tamsulosin    B-SulfaDrug104352070
(    O
e.g.    O
,    O
Flomax    O
)    O
,    O
a    O
medication    O
widely    O
prescribed    O
for    O
urinary    O
symptoms    O
associated    O
with    O
benign    O
prostatic    O
hyperplasia    O
(    O
BPH    O
)    O
.    O

In    O
addition    O
,    O
it    O
has    O
recently    O
been    O
shown    O
that    O
patients    O
taking    O
tamsulosin    B-SulfaDrug104352070
(    O
Flomax    B-SulfaDrug104352070
)    O
,    O
a    O
common    O
drug    O
for    O
enlarged    O
prostate    O
,    O
are    O
prone    O
to    O
developing    O
a    O
surgical    O
complication    O
known    O
as    O
intraoperative    O
floppy    O
iris    O
syndrome    O
(    O
IFIS    O
)    O
,    O
which    O
must    O
be    O
correctly    O
managed    O
to    O
avoid    O
the    O
complication    O
posterior    O
capsule    O
rupture    O
;    O
however    O
,    O
prospective    O
studies    O
have    O
shown    O
that    O
the    O
risk    O
is    O
greatly    O
reduced    O
if    O
the    O
surgeon    O
is    O
informed    O
of    O
the    O
patient    O
's    O
history    O
with    O
the    O
drug    O
beforehand    O
,    O
and    O
has    O
appropriate    O
alternative    O
techniques    O
prepared    O
.    O

Tamsulosin    B-SulfaDrug104352070
(    O
used    O
in    O
benign    O
prostatic    O
hyperplasia    O
)    O

Today    O
tamsulosin    B-SulfaDrug104352070
is    O
the    O
first    O
line    O
treatment    O
for    O
BPH    O
and    O
is    O
a    O
selective    O
alpha-1    O
blocker    O
.    O

NS-398    B-SulfaDrug104352070

Other    O
ingredients    O
:    O
maltodextrin    O
,    O
sorbitol    O
,    O
citric    O
acid    O
,    O
sodium    O
bicarbonate    O
,    O
potassium    O
bicarbonate    O
,    O
orange    O
flavor    O
,    O
mineral    O
oil    O
,    O
acesulfame    B-SulfaDrug104352070
potassium    I-SulfaDrug104352070
,    O
and    O
sucralose    O
.    O

Option    O
is    O
a    O
"    O
low    O
Calorie    O
sports    O
drink    O
"    O
that    O
is    O
colorless    O
and    O
sweetened    O
with    O
high    O
fructose    O
corn    O
syrup    O
,    O
sucralose    O
,    O
and    O
acesulfame    B-SulfaDrug104352070
potassium    I-SulfaDrug104352070
,    O
to    O
provide    O
sugar    O
-    O
conscious    O
consumers    O
with    O
another    O
rehydration    O
choice    O
.    O

Acesulfame    B-SulfaDrug104352070
potassium    I-SulfaDrug104352070
,    O
also    O
known    O
as    O
acesulfame    B-SulfaDrug104352070
K    I-SulfaDrug104352070
(    O
K    B-SulfaDrug104352070
is    O
the    O
symbol    O
for    O
potassium    O
)    O
or    O
Ace    B-SulfaDrug104352070
K    I-SulfaDrug104352070
,    O
is    O
a    O
calorie    O
-    O
free    O
sugar    O
substitute    O
(    O
artificial    O
sweetener    O
)    O
often    O
marketed    O
under    O
the    O
trade    O
names    O
Sunett    B-SulfaDrug104352070
and    O
Sweet    B-SulfaDrug104352070
One    I-SulfaDrug104352070
.    O

In    O
the    O
European    O
Union    O
,    O
it    O
is    O
known    O
under    O
the    O
E    O
number    O
(    O
additive    O
code    O
)    O
E950    B-SulfaDrug104352070
.    O

The    O
diet    O
variety    O
is    O
sweetened    O
with    O
a    O
mixture    O
of    O
acesulfame    B-SulfaDrug104352070
potassium    I-SulfaDrug104352070
and    O
sucralose    O
,    O
the    O
latter    O
being    O
more    O
commonly    O
known    O
under    O
the    O
brand    O
name    O
Splenda    O
.    O

On    O
June    O
30    O
,    O
1998    O
,    O
the    O
artificial    O
sweetener    O
acesulfame    B-SulfaDrug104352070
potassium    I-SulfaDrug104352070
(    O
Ace    O
-    O
K    O
)    O
was    O
approved    O
for    O
use    O
by    O
the    O
Food    O
and    O
Drug    O
Administration    O
.    O

The    O
original    O
formulation    O
was    O
sweetened    O
with    O
aspartame    O
and    O
acesulfame    B-SulfaDrug104352070
potassium    I-SulfaDrug104352070
.    O

In    O
some    O
markets    O
it    O
was    O
sweetened    O
with    O
high    O
fructose    O
corn    O
syrup    O
,    O
sugar    O
,    O
acesulfame    B-SulfaDrug104352070
potassium    I-SulfaDrug104352070
,    O
and    O
sucralose    O
,    O
and    O
marketed    O
toward    O
drinkers    O
of    O
full    O
-    O
calorie    O
Pepsi    O
,    O
and    O
those    O
who    O
do    O
not    O
enjoy    O
the    O
taste    O
of    O
Diet    O
Pepsi    O
,    O
Pepsi    O
ONE    O
,    O
Pepsi    O
Max    O
,    O
and    O
other    O
diet    O
colas    O
.    O

Its    O
half    O
-    O
life    O
under    O
hot    O
or    O
acidic    O
conditions    O
is    O
about    O
twice    O
as    O
long    O
as    O
aspartame    O
's    O
,    O
although    O
some    O
other    O
artificial    O
sweeteners    O
,    O
including    O
saccharin    O
and    O
acesulfame    B-SulfaDrug104352070
potassium    I-SulfaDrug104352070
,    O
are    O
more    O
stable    O
yet    O
.    O

Cumberland    O
Packing    O
produces    O
other    O
table    O
top    O
sweeteners    O
,    O
including    O
"    O
NatraTaste    O
"    O
,    O
an    O
aspartame    O
-    O
based    O
zero    O
calorie    O
sweetener    O
,    O
"    O
NatraTaste    O
Gold    O
"    O
,    O
a    O
sucralose    O
-    O
based    O
zero    O
calorie    O
sweetener    O
,    O
and    O
Sweet    B-SulfaDrug104352070
One    I-SulfaDrug104352070
,    O
a    O
zero    O
calorie    O
sweetener    O
made    O
with    O
acesulfame    B-SulfaDrug104352070
potassium    I-SulfaDrug104352070
.    O

Other    O
therapeutic    O
options    O
in    O
this    O
setting    O
are    O
pazopanib    B-SulfaDrug104352070
(    O
Votrient    O
)    O
,    O
sorafenib    O
(    O
Nexavar    O
)    O
,    O
temsirolimus    O
(    O
Torisel    O
)    O
,    O
interleukin-2    O
(    O
Proleukin    O
)    O
,    O
everolimus    O
(    O
Afinitor    O
)    O
,    O
bevacizumab    O
(    O
Avastin    O
)    O
,    O
and    O
aldesleukin    O
.    O

Pazopanib    B-SulfaDrug104352070
(    O
trade    O
name    O
Votrient    B-SulfaDrug104352070
)    O
is    O
a    O
potent    O
and    O
selective    O
multi    O
-    O
targeted    O
receptor    O
tyrosine    O
kinase    O
inhibitor    O
that    O
blocks    O
tumour    O
growth    O
and    O
inhibits    O
angiogenesis    O
.    O

Pazopanib    B-SulfaDrug104352070
was    O
approved    O
for    O
renal    O
cell    O
carcinoma    O
in    O
2009    O
.    O

Mavacoxib    B-SulfaDrug104352070
(    O
trade    O
name    O
Trocoxil    B-SulfaDrug104352070
)    O
is    O
a    O
veterinary    O
drug    O
used    O
to    O
treat    O
pain    O
and    O
inflammation    O
in    O
dogs    O
with    O
degenerative    O
joint    O

SB-357,134    B-SulfaDrug104352070

Chhattisgarh    O
:    O
Bhopalpatnam    O
,    O
Madded    O
,    O
Bijapur    O
,    O
Nimed    B-SulfaDrug104352070
,    O
Bhairamgarh    O
,    O
Varetumnar    O
,    O
Gidam    O
and    O
Bagmundi    O
.    O

Fenpiverinium    O
is    O
an    O
anticholinergic    O
and    O
antispasmodic    O
compound    O
;    O
it    O
is    O
marketed    O
as    O
a    O
combination    O
drug    O
with    O
pitofenone    O
hydrochloride    O
and    O
either    O
nimesulide    B-SulfaDrug104352070
or    O
metamizole    O
in    O
Eastern    O
Europe    O
and    O
India    O
to    O
treat    O
smooth    O
muscle    O
spasms    O
and    O
pain    O
.    O

Clopamide    B-SulfaDrug104352070
(    O
trade    O
name    O
Brinaldix    B-SulfaDrug104352070
)    O
is    O
a    O
piperidine    O
diuretic    O
.    O

Ethamide    B-SulfaDrug104352070

mebutizide    B-SulfaDrug104352070
(    O
INN    O
)    O

Some    O
of    O
those    O
medicines    O
include    O
:    O
zidovudine    O
(    O
AZT    O
,    O
AIDS    O
)    O
,    O
acyclovir    O
(    O
Zovirax    O
,    O
anti    O
-    O
herpes    O
)    O
,    O
permethrin    O
(    O
Rid    O
,    O
head    O
and    O
body    O
lice    O
)    O
,    O
bupropion    O
(    O
Wellbutrin    O
,    O
antidepressant    O
)    O
,    O
colfosceril    O
palmitate    O
(    O
Exosurf    O
,    O
infant    O
acute    O
respiratory    O
distress    O
)    O
,    O
remifentanil    O
(    O
Ultiva    O
,    O
analgesic    O
/    O
anesthetic    O
)    O
,    O
sumatriptan    B-SulfaDrug104352070
(    O
Imigran    O
,    O
migraine    O
)    O
,    O
salmeterol    O
(    O
Serement    O
,    O
asthma    O
)    O
,    O
tacrine    O
(    O
Cognex    O
,    O
Alzheimers    O
)    O
,    O
gabapentin    O
(    O
Neurontin    O
,    O
epilepsy    O
and    O
neuropathic    O
pain    O
)    O
,    O
troglitazone    O
(    O
Rezulin    O
,    O
diabetes    O
)    O
,    O
and    O
atorvastatin    O
(    O
Lipitor    O
,    O
cholesterol    O
lowering    O
)    O
.    O

Sumatriptan    B-SulfaDrug104352070

Sumatriptan    B-SulfaDrug104352070

Sumatriptan    B-SulfaDrug104352070

Sumatriptan    B-SulfaDrug104352070

It    O
's    O
also    O
contraindicated    O
if    O
patient    O
is    O
taking    O
Macrolide    O
antibiotics    O
(    O
eg    O
,    O
erythromycin    O
)    O
,    O
certain    O
HIV    O
protease    O
inhibitors    O
(    O
eg    O
,    O
ritonavir    O
,    O
nelfinavir    O
,    O
indinavir    O
)    O
,    O
certain    O
azole    O
antifungals    O
(    O
eg    O
,    O
ketoconazole    O
,    O
itraconazole    O
,    O
voriconazole    O
)    O
delavirdine    O
,    O
efavirenz    O
or    O
a    O
5-HT1    O
agonist    O
(    O
eg    O
,    O
sumatriptan    B-SulfaDrug104352070
)    O
.    O

Aspirin    O
,    O
especially    O
as    O
a    O
component    O
of    O
an    O
aspirin    O
/    O
paracetamol    O
/    O
caffeine    O
combination    O
,    O
is    O
considered    O
a    O
first    O
-    O
line    O
therapy    O
in    O
the    O
treatment    O
of    O
migraine    O
,    O
and    O
comparable    O
to    O
lower    O
doses    O
of    O
sumatriptan    B-SulfaDrug104352070
.    O

:    O
C03BA13    O
Fenquizone    B-SulfaDrug104352070

dimetotiazine    B-SulfaDrug104352070
(    O
INN    O
)    O

tripamide    B-SulfaDrug104352070
(    O
INN    O
)    O

Mirodenafil    O
belongs    O
to    O
the    O
drug    O
class    O
PDE5    O
inhibitors    O
,    O
which    O
includes    O
avanafil    O
,    O
sildenafil    O
,    O
tadalafil    O
,    O
udenafil    B-SulfaDrug104352070
,    O
and    O
vardenafil    O
,    O
and    O
is    O
the    O
first    O
-    O
line    O
treatment    O
for    O
erectile    O
dysfunction    O
.    O

The    O
sulfa    B-SulfaDrug104352070
drug    I-SulfaDrug104352070
Sulfathiazole    B-SulfaDrug104352070
was    O
one    O
of    O
the    O
results    O
of    O
these    O
research    O
activities    O
.    O

Antibiotics    O
such    O
as    O
streptomycin    O
,    O
amikacin    O
,    O
tetracycline    O
,    O
doxycycline    O
,    O
carbapenems    O
,    O
ceftazidime    O
,    O
amoxicillin    O
/    O
clavulanic    O
acid    O
,    O
piperacillin    O
,    O
chloramphenicol    O
,    O
and    O
sulfathiazole    B-SulfaDrug104352070
have    O
been    O
reported    O
to    O
be    O
effective    O
against    O
the    O
bacteria    O
"    O
in    O
vitro    O
"    O
.    O

The    O
cactus    O
flesh    O
was    O
cooked    O
in    O
salted    O
water    O
and    O
the    O
solution    O
was    O
applied    O
to    O
infected    O
wounds    O
three    O
times    O
daily    O
,    O
followed    O
by    O
a    O
sulfathiazole    B-SulfaDrug104352070
powder    O
.    O

Sulfonamides    B-SulfaDrug104352070
(    O
such    O
as    O
sulfanilamide    O
,    O
sulfamethoxazole    O
,    O
and    O
mafenide    B-SulfaDrug104352070
)    O
,    O
thiazolesulfone    O
,    O
methylene    O
blue    O
,    O
and    O
naphthalene    O
should    O
also    O
be    O
avoided    O
by    O
people    O
with    O
G6PD    O
deficiency    O
as    O
they    O
antagonize    O
folate    O
synthesis    O
,    O
as    O
should    O
certain    O
analgesics    O
(    O
such    O
as    O
phenazopyridine    O
and    O
acetanilide    O
)    O
and    O
a    O
few    O
non    O
-    O
sulfa    O
antibiotics    O
(    O
nalidixic    O
acid    O
,    O
nitrofurantoin    O
,    O
isoniazid    O
,    O
dapsone    O
,    O
and    O
furazolidone    O
)    O
.    O

Mafenide    B-SulfaDrug104352070
(    O
INN    O
;    O
usually    O
as    O
mafenide    O
acetate    O
,    O
trade    O
name    O
Sulfamylon    B-SulfaDrug104352070
)    O
is    O
a    O
sulfonamide    B-SulfaDrug104352070
-    O
type    O
medication    O
used    O
as    O
an    O
antibiotic    O
.    O

Daclatasvir    O
has    O
been    O
tested    O
in    O
combination    O
regimens    O
with    O
pegylated    O
interferon    O
and    O
ribavirin    O
,    O
as    O
well    O
as    O
with    O
other    O
direct    O
-    O
acting    O
antiviral    O
agents    O
including    O
asunaprevir    B-SulfaDrug104352070
and    O
sofosbuvir    O
.    O

Diulo    B-SulfaDrug104352070

Metolazone    B-SulfaDrug104352070
(    O
INN    O
)    O

Spironolactone    O
is    O
also    O
formulated    O
in    O
combination    O
with    O
a    O
variety    O
of    O
other    O
drugs    O
,    O
including    O
with    O
hydrochlorothiazide    O
as    O
Aldactazide    O
,    O
with    O
hydroflumethiazide    O
as    O
Aldactide    O
,    O
Lasilacton    O
,    O
Lasilactone    O
,    O
and    O
Spiromide    O
,    O
with    O
altizide    O
as    O
Aldactacine    O
and    O
Aldactazine    O
,    O
with    O
furosemide    O
as    O
Fruselac    O
,    O
with    O
benazepril    O
as    O
Cardalis    O
(    O
veterinary    O
)    O
,    O
with    O
metolazone    B-SulfaDrug104352070
as    O
Metolactone    O
,    O
with    O
bendroflumethiazide    O
as    O
Sali    O
-    O
Aldopur    O
,    O
and    O
with    O
torasemide    O
as    O
Dytor    O
Plus    O
,    O
Torlactone    O
,    O
and    O
Zator    O
Plus    O
.    O

BAY    B-SulfaDrug104352070
57-1293    I-SulfaDrug104352070
,    O
AIC316    O
or    O
pritelivir    O

However    O
,    O
newly    O
developed    O
IP    O
agonists    O
with    O
favorable    O
pharmacological    O
features    O
such    O
as    O
Selexipag    B-SulfaDrug104352070
have    O
been    O
granted    O
by    O
the    O
US    O
FDA    O
Orphan    O
Drug    O
status    O
for    O
the    O
treatment    O
of    O
pulmonary    O
hypertension    O
.    O

SB-258,585    B-SulfaDrug104352070

Hesperadin    B-SulfaDrug104352070
is    O
an    O
aurora    O
kinase    O
inhibitor    O
.    O

Topoisomerase    O
II    O
inhibitors    O
:    O
etoposide    O
(    O
VP-16    O
)    O
,    O
teniposide    O
,    O
doxorubicin    O
,    O
daunorubicin    O
,    O
mitoxantrone    O
,    O
amsacrine    B-SulfaDrug104352070
,    O
ellipticines    O
,    O
aurintricarboxylic    O
acid    O
,    O
and    O
HU-331    O
,    O
a    O
quinolone    O
synthesized    O
from    O
cannabidiol    O
.    O

"    O
eukaryotic    O
"    O
type    O
II    O
topoisomerase    O
inhibitors    O
(    O
topo    O
II    O
)    O
:    O
amsacrine    B-SulfaDrug104352070
,    O
etoposide    O
,    O
etoposide    O
phosphate    O
,    O
teniposide    O
and    O
doxorubicin    O
.    O

3-Hydroxytetrahydrofuran    O
is    O
an    O
intermediate    O
to    O
the    O
AIDS    O
drugs    O
amprenavir    B-SulfaDrug104352070
and    O
fosamprenavir    O
.    O

Many    O
of    O
these    O
uses    O
have    O
been    O
exemplified    O
in    O
the    O
syntheses    O
of    O
various    O
pharmaceuticals    O
including    O
the    O
β-blocker    O
(    O
"    O
S")-propranolol    O
,    O
the    O
HIV    O
protease    O
inhibitor    O
Amprenavir    B-SulfaDrug104352070
(    O
Vertex    O
478    O
)    O
,    O
and    O
construction    O
of    O
the    O
carbohydrate    O
subunit    O
of    O
the    O
anthracycline    O
class    O
of    O
antibiotics    O
,    O
L    O
-    O
Acosamine    O
.    O

:    O
QP51AG03    O
Sulfaquinoxaline    B-SulfaDrug104352070

Almotriptan    B-SulfaDrug104352070

Methyclothiazide    B-SulfaDrug104352070
(    O
INN    O
)    O

meloxicam    B-SulfaDrug104352070

Bearers    O
of    O
this    O
SNP    O
may    O
or    O
may    O
not    O
show    O
increased    O
risk    O
of    O
developing    O
acute    O
gastrointestinal    O
bleeding    O
during    O
the    O
use    O
of    O
non    O
-    O
steroidal    O
anti    O
-    O
inflammatory    O
drugs    O
(    O
NSAIDs    O
)    O
that    O
are    O
its    O
substrates    O
such    O
as    O
aceclofenac    O
,    O
celecoxib    O
,    O
diclofenac    O
,    O
ibuprofen    O
,    O
indomethacin    O
,    O
lornoxicam    O
,    O
meloxicam    B-SulfaDrug104352070
,    O
naproxen    O
,    O
piroxicam    O
,    O
tenoxicam    O
,    O
and    O
valdecoxib    O
.    O

The    O
existing    O
nonsteroidal    O
anti    O
-    O
inflammatory    O
drugs    O
(    O
NSAIDs    O
)    O
differ    O
in    O
their    O
relative    O
specificities    O
for    O
COX-2    O
and    O
COX-1    O
;    O
while    O
aspirin    O
and    O
ibuprofen    O
inhibit    O
COX-2    O
and    O
COX-1    O
enzymes    O
,    O
other    O
NSAIDs    O
appear    O
to    O
have    O
partial    O
COX-2    O
specificity    O
,    O
particularly    O
meloxicam    B-SulfaDrug104352070
(    O
Mobic    B-SulfaDrug104352070
)    O
.    O

A    O
genetic    O
condition    O
,    O
and    O
a    O
side    O
effect    O
of    O
sulphonamides    B-SulfaDrug104352070
(    O
a    O
family    O
of    O
antibiotics    O
)    O
can    O
also    O
cause    O
this    O
appearance    O
.    O

Despite    O
only    O
moderate    O
efficacy    O
it    O
is    O
well    O
favoured    O
due    O
to    O
few    O
resistance    O
issues    O
and    O
is    O
commonly    O
used    O
in    O
conjunction    O
with    O
sulfonamide    B-SulfaDrug104352070
prophylactically    O
in    O
chickens    O
and    O
cattle    O
as    O
a    O
coccidiostat    O
.    O

If    O
the    O
patient    O
receiving    O
procaine    O
is    O
on    O
sulfonamide    B-SulfaDrug104352070
antibiotics    O
such    O
as    O
bactrim    O
the    O
antibiotic    O
effect    O
will    O
be    O
antagonized    O
by    O
providing    O
a    O
new    O
source    O
of    O
PABA    O
to    O
the    O
microbe    O
for    O
subsequent    O
synthesis    O
of    O
folic    O
acid    O
.    O

Drugs    O
that    O
potentiate    O
or    O
prolong    O
the    O
effects    O
of    O
sulfonylureas    O
and    O
therefore    O
increase    O
the    O
risk    O
of    O
hypoglycemia    O
include    O
acetylsalicylic    O
acid    O
and    O
derivatives    O
,    O
allopurinol    O
,    O
sulfonamide    B-SulfaDrug104352070
,    O
and    O
fibrates    O
.    O

Sulfonylureas    O
were    O
discovered    O
,    O
in    O
1942    O
,    O
by    O
the    O
chemist    O
Marcel    O
Janbon    O
and    O
co    O
-    O
workers    O
,    O
who    O
were    O
studying    O
sulfonamide    B-SulfaDrug104352070
antibiotics    O
and    O
discovered    O
that    O
the    O
compound    O
sulfonylurea    O
induced    O
hypoglycemia    O
in    O
animals    O
.    O

It    O
was    O
known    O
that    O
penicillin    O
was    O
more    O
effective    O
than    O
sulfa    B-SulfaDrug104352070
drugs    I-SulfaDrug104352070
,    O
and    O
that    O
its    O
use    O
reduced    O
mortality    O
,    O
severity    O
of    O
long    O
-    O
term    O
wound    O
trauma    O
,    O
and    O
recovery    O
time    O
.    O

In    O
fact    O
,    O
it    O
was    O
shown    O
that    O
both    O
YdaH    O
and    O
MtrF    O
participate    O
as    O
antibiotic    O
efflux    O
pumps    O
,    O
mediating    O
bacterial    O
resistance    O
to    O
sulfonamide    B-SulfaDrug104352070
antimetabolite    I-SulfaDrug104352070
drugs    I-SulfaDrug104352070
.    O

Because    O
furosemide    O
,    O
torsemide    O
and    O
bumetanide    B-SulfaDrug104352070
are    O
technically    O
sulfa    B-SulfaDrug104352070
drugs    O
,    O
there    O
is    O
a    O
theoretical    O
risk    O
that    O
patients    O
sensitive    O
to    O
sulfonamides    B-SulfaDrug104352070
may    O
be    O
sensitive    O
to    O
these    O
loop    O
diuretics    O
.    O

His    O
other    O
research    O
included    O
work    O
on    O
chemotherapy    O
,    O
sulfa    B-SulfaDrug104352070
drug    I-SulfaDrug104352070
,    O
the    O
sympathetic    O
nervous    O
system    O
,    O
the    O
pharmacology    O
of    O
curare    O
,    O
and    O
other    O
neuropharmacological    O
interests    O
.    O

Sulfonamides    B-SulfaDrug104352070

Drugs    O
most    O
commonly    O
implicated    O
are    O
penicillin    O
,    O
sulphonamides    B-SulfaDrug104352070
and    O
thiazide    O
diuretics    O
.    O

It    O
combines    O
sodium    O
sulfacetamide    O
,    O
a    O
sulfonamide    B-SulfaDrug104352070
antibiotic    O
,    O
and    O
sulfur    O
,    O
a    O
keratolytic    O
agent    O
.    O

Les    O
died    O
3    O
months    O
after    O
graduation    O
,    O
in    O
1936    O
,    O
from    O
a    O
ruptured    O
appendix    O
,    O
shortly    O
before    O
the    O
discovery    O
of    O
sulfa    B-SulfaDrug104352070
and    O
long    O
before    O
antibiotics    O
.    O

Mafenide    B-SulfaDrug104352070
(    O
INN    O
;    O
usually    O
as    O
mafenide    O
acetate    O
,    O
trade    O
name    O
Sulfamylon    B-SulfaDrug104352070
)    O
is    O
a    O
sulfonamide    B-SulfaDrug104352070
-    O
type    O
medication    O
used    O
as    O
an    O
antibiotic    O
.    O

The    O
mainstays    O
of    O
treatment    O
are    O
the    O
administration    O
of    O
broad    O
-    O
spectrum    O
antibiotics    O
(    O
typically    O
potentiated    B-SulfaDrug104352070
sulfonamides    I-SulfaDrug104352070
or    O
penicillin    O
and    O
streptomycin    O
,    O
but    O
doxycycline    O
may    O
be    O
the    O
most    O
effective    O
)    O
.    O

This    O
makes    O
it    O
a    O
useful    O
target    O
for    O
sulfonamide    B-SulfaDrug104352070
antibiotics    O
,    O
which    O
compete    O
with    O
the    O
PABA    O
precursor    O
.    O

Chemically    O
it    O
is    O
a    O
sulfonamide    B-SulfaDrug104352070
.    O

Immunoglobulin    O
therapy    O
continued    O
to    O
be    O
a    O
first    O
line    O
therapy    O
in    O
the    O
treatment    O
of    O
severe    O
respiratory    O
diseases    O
until    O
the    O
1930s    O
,    O
even    O
after    O
sulfonamides    B-SulfaDrug104352070
were    O
introduced    O
.    O

On    O
the    O
other    O
hand    O
,    O
the    O
drug    O
(    O
a    O
)    O
elevates    O
risk    O
for    O
floppy    O
iris    O
syndrome    O
,    O
and    O
(    O
b    O
)    O
might    O
show    O
adverse    O
drug    O
reactions    O
(    O
ADRs    O
)    O
characteristic    O
of    O
the    O
sulfa    B-SulfaDrug104352070
related    O
drugs    O
.    O

Protargol    O
stayed    O
in    O
use    O
until    O
sulfa    B-SulfaDrug104352070
drugs    I-SulfaDrug104352070
and    O
then    O
antibiotics    O
became    O
available    O
in    O
the    O
1940s    O
.    O

Sulphonamides    B-SulfaDrug104352070
:    O
clorsulon    O
(    O
Ivomec    O
Plus    O
)    O

Trimethoprim    O
/    O
sulfamethoxazole    O
should    O
not    O
be    O
taken    O
by    O
anyone    O
with    O
a    O
history    O
of    O
sulfa    B-SulfaDrug104352070
allergy    O
.    O

The    O
first    O
sulfonamide    B-SulfaDrug104352070
and    O
the    O
first    O
systemically    O
active    O
antibacterial    O
drug    O
,    O
Prontosil    O
,    O
was    O
developed    O
by    O
a    O
research    O
team    O
led    O
by    O
Gerhard    O
Domagk    O
in    O
1932    O
or    O
1933    O
at    O
the    O
Bayer    O
Laboratories    O
of    O
the    O
IG    O
Farben    O
conglomerate    O
in    O
Germany    O
,    O
for    O
which    O
Domagk    O
received    O
the    O
1939    O
Nobel    O
Prize    O
in    O
Physiology    O
or    O
Medicine    O
.    O

Those    O
that    O
target    O
the    O
bacterial    O
cell    O
wall    O
(    O
penicillins    O
and    O
cephalosporins    O
)    O
or    O
the    O
cell    O
membrane    O
(    O
polymyxins    O
)    O
,    O
or    O
interfere    O
with    O
essential    O
bacterial    O
enzymes    O
(    O
rifamycins    O
,    O
lipiarmycins    O
,    O
quinolones    O
,    O
and    O
sulfonamides    B-SulfaDrug104352070
)    O
have    O
bactericidal    O
activities    O
.    O

Compounds    O
that    O
are    O
still    O
isolated    O
from    O
living    O
organisms    O
are    O
the    O
aminoglycosides    O
,    O
whereas    O
other    O
antibacterials    O
—    O
for    O
example    O
,    O
the    O
sulfonamides    B-SulfaDrug104352070
,    O
the    O
quinolones    O
,    O
and    O
the    O
oxazolidinones    O
—    O
are    O
produced    O
solely    O
by    O
chemical    O
synthesis    O
.    O

It    O
also    O
excluded    O
synthetic    O
antibacterial    O
compounds    O
such    O
as    O
the    O
sulfonamides    B-SulfaDrug104352070
.    O

#    O
Alteration    O
of    O
metabolic    O
pathway    O
:    O
for    O
example    O
,    O
some    O
sulfonamide    B-SulfaDrug104352070
-    O
resistant    O
bacteria    O
do    O
not    O
require    O
para    O
-    O
aminobenzoic    O
acid    O
(    O
PABA    O
)    O
,    O
an    O
important    O
precursor    O
for    O
the    O
synthesis    O
of    O
folic    O
acid    O
and    O
nucleic    O
acids    O
in    O
bacteria    O
inhibited    O
by    O
sulfonamides    O
,    O
instead    O
,    O
like    O
mammalian    O
cells    O
,    O
they    O
turn    O
to    O
using    O
preformed    O
folic    O
acid    O
.    O

Churchill    O
was    O
saved    O
by    O
Lord    O
Moran    O
,    O
using    O
sulphonamides    B-SulfaDrug104352070
,    O
since    O
he    O
had    O
no    O
experience    O
with    O
penicillin    O
,    O
when    O
Churchill    O
fell    O
ill    O
in    O
Carthage    O
in    O
Tunisia    O
in    O
1943    O
.    O
"    O
The    O
Daily    O
Telegraph    O
"    O
and    O
"    O
The    O
Morning    O
Post    O
"    O
on    O
21    O
December    O
1943    O
wrote    O
that    O
he    O
had    O
been    O
saved    O
by    O
penicillin    O
.    O

It    O
is    O
highly    O
probable    O
that    O
the    O
correct    O
information    O
about    O
the    O
sulphonamide    B-SulfaDrug104352070
did    O
not    O
reach    O
the    O
newspapers    O
because    O
,    O
since    O
the    O
original    O
sulphonamide    O
antibacterial    O
,    O
Prontosil    O
,    O
had    O
been    O
a    O
discovery    O
by    O
the    O
German    O
laboratory    O
Bayer    O
,    O
and    O
as    O
Britain    O
was    O
at    O
war    O
with    O
Germany    O
at    O
the    O
time    O
,    O
it    O
was    O
thought    O
better    O
to    O
raise    O
British    O
morale    O
by    O
associating    O
Churchill    O
's    O
cure    O
with    O
a    O
British    O
discovery    O
,    O
penicillin    O
.    O

piretanide    B-SulfaDrug104352070
(    O
INN    O
)    O

Diucifon    B-SulfaDrug104352070
is    O
a    O
leprostatic    O
agent    O
.    O

Drug    O
-    O
induced    O
QT    O
prolongation    O
is    O
seen    O
with    O
a    O
QT    O
interval    O
above    O
0.45    O
ms    O
on    O
the    O
ECG    O
and    O
is    O
usually    O
a    O
result    O
of    O
treatment    O
by    O
anti    O
-    O
arrhythmic    O
drugs    O
,    O
such    O
as    O
amiodarone    O
and    O
sotalol    B-SulfaDrug104352070
,    O
or    O
a    O
number    O
of    O
other    O
drugs    O
that    O
have    O
been    O
reported    O
to    O
cause    O
this    O
problem    O
(    O
e.g.    O
,    O
cisapride    O
)    O
.    O

Sotalol    B-SulfaDrug104352070

Examples    O
include    O
Sotalol    B-SulfaDrug104352070
,    O
ibutilide    B-SulfaDrug104352070
,    O
sematilide    B-SulfaDrug104352070
,    O
Dronedarone    O
,    O
Dofetilide    B-SulfaDrug104352070
,    O
E-4031    O
,    O
and    O
Bitopertin    O
.    O

Class    O
III    O
—    O
Potassium    O
channel    O
blockers    O
(    O
amiodarone    O
,    O
sotalol    B-SulfaDrug104352070
,    O
ibutilide    B-SulfaDrug104352070
,    O
dofetilide    B-SulfaDrug104352070
,    O
dronedarone    O
)    O

Sotalol    B-SulfaDrug104352070

polythiazide    B-SulfaDrug104352070

Braf    O
inhibitors    O
(    O
vemurafenib    B-SulfaDrug104352070
,    O
dabrafenib    O
,    O
LGX818    O
)    O
used    O
to    O
treat    O
metastatic    O
melanoma    O
that    O
harbors    O
BRAF    O
V600E    O
mutation    O

Vemurafenib    B-SulfaDrug104352070
(    O
Zelboraf    O
)    O

Vemurafenib    B-SulfaDrug104352070
.    O

2011    O
–    O
Zelboraf    B-SulfaDrug104352070
(    O
vemurafenib    O
)    O
:    O
For    O
the    O
treatment    O
of    O
a    O
type    O
of    O
skin    O
cancer    O
called    O
melanoma    O
that    O
has    O
spread    O
to    O
other    O
parts    O
of    O
the    O
body    O
or    O
can    O
not    O
be    O
removed    O
by    O
surgery    O
,    O
and    O
has    O
a    O
certain    O
type    O
of    O
abnormal    O
BRAF    O
gene    O
.    O

fasudil    B-SulfaDrug104352070
(    O
INN    O
)    O

Silver    B-SulfaDrug104352070
sulfadiazine    I-SulfaDrug104352070

Silver    B-SulfaDrug104352070
sulfadiazine    I-SulfaDrug104352070
(    O
a    O
type    O
of    O
antibiotic    O
)    O
is    O
not    O
recommended    O
as    O
it    O
potentially    O
prolongs    O
healing    O
time    O
.    O

Topical    O
silver    B-SulfaDrug104352070
sulfadiazine    I-SulfaDrug104352070
for    O
burn    O
wounds    O

clofenamide    B-SulfaDrug104352070
(    O
INN    O
)    O

Sonepiprazole    B-SulfaDrug104352070
—    O
dopaminergic    O

Class    O
III    O
—    O
Potassium    O
channel    O
blockers    O
(    O
amiodarone    O
,    O
sotalol    B-SulfaDrug104352070
,    O
ibutilide    B-SulfaDrug104352070
,    O
dofetilide    B-SulfaDrug104352070
,    O
dronedarone    O
)    O

Dofetilide    B-SulfaDrug104352070

In    O
the    O
same    O
month    O
the    O
company    O
announced    O
it    O
would    O
acquire    O
Zonegran    B-SulfaDrug104352070
in    O
the    O
United    O
States    O
and    O
Puerto    O
Rico    O
,    O
for    O
$    O
90    O
million    O
.    O

Sultone    O
oximes    O
are    O
key    O
intermediates    O
in    O
the    O
synthesis    O
of    O
the    O
anti    O
-    O
convulsant    O
drug    O
zonisamide    B-SulfaDrug104352070
.    O

Zonisamide    B-SulfaDrug104352070
is    O
a    O
medication    O
used    O
to    O
treat    O
the    O
symptoms    O
of    O
epilepsy    O
and    O
Parkinson    O
's    O
disease    O
.    O

It    O
can    O
also    O
be    O
a    O
side    O
effect    O
of    O
benzodiazepines    O
or    O
opioids    O
,    O
particularly    O
if    O
used    O
in    O
larger    O
doses    O
for    O
recreation    O
,    O
the    O
anti    O
-    O
epileptic    O
drugs    O
Phenytoin    O
and    O
Zonisamide    B-SulfaDrug104352070
,    O
and    O
the    O
anti    O
-    O
convulsant    O
drug    O
Lamotrigine    O
,    O
as    O
well    O
as    O
the    O
hypnotic    O
drug    O
Zolpidem    O
and    O
the    O
dissociative    O
drugs    O
Ketamine    O
and    O
Dextromethorphan    O
.    O

Belinostat    B-SulfaDrug104352070
(    O
trade    O
name    O
Beleodaq    B-SulfaDrug104352070
,    O
previously    O
known    O
as    O
PXD101    B-SulfaDrug104352070
)    O
is    O
a    O
histone    O
deacetylase    O
inhibitor    O
drug    O
developed    O
by    O
TopoTarget    O
for    O
the    O
treatment    O
of    O
hematological    O
malignancies    O
and    O
solid    O
tumors    O
.    O

Alkalization    O
of    O
the    O
urine    O
with    O
acetazolamide    B-SulfaDrug104352070
or    O
sodium    O
bicarbonate    O
is    O
controversial    O
.    O

Barrios    O
finished    O
the    O
Olympic    O
discus    O
competition    O
in    O
2008    O
in    O
the    O
second    O
place    O
,    O
but    O
was    O
disqualified    O
by    O
the    O
IOC    O
on    O
September    O
1    O
,    O
2016    O
because    O
of    O
doping    O
due    O
to    O
a    O
sample    O
reanalysis    O
which    O
resulted    O
in    O
a    O
positive    O
test    O
for    O
the    O
prohibited    O
substance    O
Acetazolamide    B-SulfaDrug104352070
.    O

Allergic    O
(    O
acetazolamide    B-SulfaDrug104352070
,    O
amitriptyline    O
)    O

It    O
is    O
also    O
known    O
to    O
be    O
a    O
weak    O
carbonic    O
anhydrase    O
inhibitor    O
(    O
similarly    O
to    O
the    O
anticonvulsant    O
,    O
acetazolamide    B-SulfaDrug104352070
)    O
.    O

Raised    O
intracranial    O
pressure    O
,    O
if    O
severe    O
or    O
threatening    O
vision    O
,    O
may    O
require    O
therapeutic    O
lumbar    O
puncture    O
(    O
removal    O
of    O
excessive    O
cerebrospinal    O
fluid    O
)    O
,    O
medication    O
(    O
acetazolamide    B-SulfaDrug104352070
)    O
,    O
or    O
neurosurgical    O
treatment    O
(    O
optic    O
nerve    O
sheath    O
fenestration    O
or    O
shunting    O
)    O
.    O

They    O
are    O
available    O
as    O
eye    O
drops    O
(    O
Trusopt    O
and    O
Azopt    O
)    O
and    O
pills    O
(    O
Diamox    B-SulfaDrug104352070
and    O
Neptazane    B-SulfaDrug104352070
)    O
.    O

It    O
takes    O
about    O
four    O
days    O
at    O
any    O
given    O
altitude    O
and    O
can    O
be    O
enhanced    O
by    O
drugs    O
such    O
as    O
acetazolamide    B-SulfaDrug104352070
.    O

For    O
example    O
,    O
acetazolamide    B-SulfaDrug104352070
and    O
ammonium    O
chloride    O
are    O
known    O
to    O
enhance    O
the    O
intoxicating    O
effect    O
of    O
salicylates    O
,    O
and    O
alcohol    O
also    O
increases    O
the    O
gastrointestinal    O
bleeding    O
associated    O
with    O
these    O
types    O
of    O
drugs    O
.    O

However    O
,    O
in    O
pre    O
-    O
Olympic    O
drug    O
testing    O
by    O
the    O
International    O
Olympic    O
Committee    O
(    O
IOC    O
)    O
,    O
Öhlund    O
tested    O
positive    O
for    O
the    O
banned    O
substance    O
acetazolamide    B-SulfaDrug104352070
.    O

The    O
substance    O
was    O
inadvertently    O
ingested    O
after    O
Öhlund    O
took    O
Diamox    B-SulfaDrug104352070
,    O
a    O
drug    O
he    O
had    O
used    O
previously    O
while    O
undergoing    O
eye    O
surgery    O
.    O

Amiloride    O
hydrochloride    O
with    O
cyclopenthiazide    B-SulfaDrug104352070

Deracoxib    B-SulfaDrug104352070
(    O
trade    O
name    O
Deramaxx    B-SulfaDrug104352070
)    O
is    O
a    O
nonsteroidal    O
anti    O
-    O
inflammatory    O
drug    O
(    O
NSAID    O
)    O
of    O
the    O
coxib    O
class    O
,    O
used    O
in    O
dogs    O
to    O
treat    O
pain    O
associated    O
with    O
osteoarthritis    O
,    O
or    O
to    O
prevent    O
pain    O
following    O
orthopedic    O
or    O
dental    O
surgery    O
.    O

selective    O
ETA    O
receptor    O
antagonists    O
(    O
sitaxentan    B-SulfaDrug104352070
,    O
ambrisentan    O
,    O
atrasentan    O
,    O
BQ-123    O
,    O
zibotentan    O
)    O
,    O
which    O
affect    O
endothelin    O
A    O
receptors    O
.    O

The    O
interaction    O
between    O
sofosbuvir    O
and    O
a    O
number    O
of    O
other    O
drugs    O
,    O
such    O
as    O
ciclosporin    O
,    O
darunavir    B-SulfaDrug104352070
/    O
ritonavir    O
,    O
efavirenz    O
,    O
emtricitabine    O
,    O
methadone    O
,    O
raltegravir    O
,    O
rilpivirine    O
,    O
tacrolimus    O
,    O
or    O
tenofovir    O
disoproxil    O
,    O
were    O
evaluated    O
in    O
clinical    O
trials    O
and    O
no    O
dose    O
adjustment    O
is    O
needed    O
for    O
any    O
of    O
these    O
drugs    O
.    O

Darunavir    B-SulfaDrug104352070

Darunavir    B-SulfaDrug104352070
(    O
TMC114    O
,    O
tradename    O
Prezista    O
)    O
,    O
a    O
protease    O
inhibitor    O

:    O
N05AB08    O
Thioproperazine    B-SulfaDrug104352070

Lactation    O
failure    O
can    O
be    O
treated    O
with    O
a    O
galactagogue    O
(    O
lactation    O
-    O
promoting    O
agent    O
)    O
such    O
as    O
a    O
D2    O
receptor    O
antagonist    O
like    O
domperidone    O
,    O
metoclopramide    O
,    O
or    O
certain    O
antipsychotics    O
like    O
chlorpromazine    O
,    O
haloperidol    O
,    O
sulpiride    B-SulfaDrug104352070
,    O
or    O
risperidone    O
,    O
an    O
oxytocic    O
such    O
as    O
oxytocin    O
or    O
an    O
analogue    O
like    O
carbetocin    O
or    O
demoxytocin    O
,    O
with    O
GH    O
(    O
or    O
potentially    O
with    O
a    O
growth    O
hormone    O
secretagogue    O
,    O
alternatively    O
)    O
,    O
or    O
with    O
thyrotropin    O
-    O
releasing    O
hormone    O
(    O
TRH    O
)    O
or    O
thyroid    O
-    O
stimulating    O
hormone    O
(    O
TSH    O
)    O
.    O

That    O
research    O
project    O
also    O
produced    O
the    O
product    O
sulpiride    B-SulfaDrug104352070
.    O

The    O
D2    O
receptor    O
is    O
involved    O
in    O
the    O
regulation    O
of    O
prolactin    O
secretion    O
,    O
and    O
agonists    O
of    O
the    O
receptor    O
such    O
as    O
bromocriptine    O
and    O
cabergoline    O
decrease    O
prolactin    O
levels    O
while    O
antagonists    O
of    O
the    O
receptor    O
such    O
as    O
domperidone    O
,    O
metoclopramide    O
,    O
haloperidol    O
,    O
risperidone    O
,    O
and    O
sulpiride    B-SulfaDrug104352070
increase    O
prolactin    O
levels    O
.    O

Quetiapine    O
,    O
sulpiride    B-SulfaDrug104352070
and    O
olanzapine    O
,    O
the    O
atypical    O
neuroleptic    O
agents    O
,    O
are    O
less    O
likely    O
to    O
yield    O
drug    O
-    O
induced    O
parkinsonism    O
and    O
tardive    O
dyskinesia    O

Examples    O
include    O
Sotalol    B-SulfaDrug104352070
,    O
ibutilide    B-SulfaDrug104352070
,    O
sematilide    B-SulfaDrug104352070
,    O
Dronedarone    O
,    O
Dofetilide    B-SulfaDrug104352070
,    O
E-4031    O
,    O
and    O
Bitopertin    O
.    O

Examples    O
include    O
Sotalol    B-SulfaDrug104352070
,    O
ibutilide    B-SulfaDrug104352070
,    O
sematilide    B-SulfaDrug104352070
,    O
Dronedarone    O
,    O
Dofetilide    B-SulfaDrug104352070
,    O
E-4031    O
,    O
and    O
Bitopertin    O
.    O

Class    O
III    O
—    O
Potassium    O
channel    O
blockers    O
(    O
amiodarone    O
,    O
sotalol    B-SulfaDrug104352070
,    O
ibutilide    B-SulfaDrug104352070
,    O
dofetilide    B-SulfaDrug104352070
,    O
dronedarone    O
)    O

To    O
combat    O
the    O
danger    O
of    O
dysentery    O
,    O
Ford    O
had    O
all    O
available    O
supplies    O
of    O
sulphaguanidine    B-SulfaDrug104352070
in    O
Australia    O
shipped    O
up    O
to    O
New    O
Guinea    O
,    O
where    O
Australian    O
forces    O
were    O
fighting    O
a    O
desperate    O
campaign    O
against    O
the    O
Japanese    O
.    O

Tosyl    B-SulfaDrug104352070
phenylalanyl    I-SulfaDrug104352070
chloromethyl    I-SulfaDrug104352070
ketone    I-SulfaDrug104352070
(    O
TPCK    B-SulfaDrug104352070
)    O
is    O
a    O
protease    O
inhibitor    O
.    O

Doripenem    B-SulfaDrug104352070
is    O
an    O
ultra    O
-    O
broad    O
-    O
spectrum    O
injectable    O
antibiotic    O
.    O

It    O
was    O
launched    O
by    O
Shionogi    O
Co.    O
of    O
Japan    O
under    O
the    O
brand    O
name    O
Finibax    B-SulfaDrug104352070
in    O
2005    O
and    O

Camphorsultam    B-SulfaDrug104352070
,    O
also    O
known    O
as    O
bornanesultam    B-SulfaDrug104352070
,    O
is    O
a    O
crystalline    O
solid    O
primarily    O
used    O
as    O
a    O
chiral    O
auxiliary    O
in    O
the    O
synthesis    O
of    O
other    O
chemicals    O
with    O
a    O
specific    O
desired    O
stereoselectivity    O
.    O

clorexolone    B-SulfaDrug104352070
(    O
INN    O
)    O

Benzthiazide    B-SulfaDrug104352070
(    O
BAN    O
/    O
INN    O
,    O
also    O
known    O
as    O
benzothiazide    B-SulfaDrug104352070
;    O
trade    O
names    O
Aquatag    B-SulfaDrug104352070
,    O
Dihydrex    B-SulfaDrug104352070
,    O
Diucen    B-SulfaDrug104352070
,    O
Edemax    B-SulfaDrug104352070
,    O
Exna    B-SulfaDrug104352070
,    O
Foven    B-SulfaDrug104352070
and    O
others    O
)    O
is    O
a    O
thiazide    O
diuretic    O
used    O
in    O
the    O
treatment    O
of    O
high    O
blood    O
pressure    O
and    O
edema    O
.    O

The    O
inhibitors    O
of    O
the    O
target    O
effects    O
of    O
thromboxane    O
are    O
the    O
thromboxane    O
receptor    O
antagonist    O
,    O
including    O
terutroban    B-SulfaDrug104352070
.    O

:    O
N03AX03    O
Sultiame    B-SulfaDrug104352070

Bumetanide    B-SulfaDrug104352070
(    O
trade    O
names    O
Bumex    B-SulfaDrug104352070
or    O
Burinex    B-SulfaDrug104352070
)    O
is    O
a    O
loop    O
diuretic    O
of    O
the    O
sulfamyl    O
category    O
,    O
most    O
often    O
used    O
to    O
treat    O
heart    O
failure    O
.    O

He    O
had    O
been    O
using    O
StarCaps    O
,    O
which    O
contained    O
the    O
illegal    O
loop    O
diuretic    O
bumetanide    B-SulfaDrug104352070
,    O
which    O
is    O
used    O
to    O
mask    O
steroids    O
or    O
performance    O
-    O
enhancing    O
drugs    O
(    O
PEDs    O
)    O
.    O

For    O
nonresponders    O
,    O
a    O
loop    O
diuretic    O
may    O
also    O
be    O
added    O
and    O
generally    O
,    O
furosemide    O
is    O
added    O
at    O
a    O
dose    O
of    O
40    O
mg    O
/    O
day    O
(    O
max    O
160    O
mg    O
/    O
day    O
)    O
,    O
or    O
alternatively    O
(    O
bumetanide    B-SulfaDrug104352070
or    O
torasemide    O
)    O
.    O

Schleck    O
was    O
withdrawn    O
from    O
the    O
race    O
by    O
his    O
team    O
after    O
traces    O
of    O
xipamide    B-SulfaDrug104352070
,    O
a    O
banned    O
sulfonamide    O
diuretic    O
drug    O
,    O
were    O
found    O
in    O
the    O
A    O
-    O
sample    O
of    O
his    O
urine    O
;    O
the    O
presence    O
of    O
xipamide    O
was    O
later    O
confirmed    O
by    O
the    O
B    O
-    O
sample    O
.    O

Schleck    O
quit    O
the    O
race    O
after    O
traces    O
of    O
xipamide    B-SulfaDrug104352070
,    O
a    O
banned    O
sulfonamide    O
diuretic    O
drug    O
,    O
were    O
found    O
in    O
the    O
A    O
-    O
sample    O
of    O
his    O
urine    O
,    O
and    O
was    O
later    O
confirmed    O
by    O
the    O
B    O
-    O
sample    O
.    O

Azosemide    B-SulfaDrug104352070
is    O
a    O
high    O
-    O
ceiling    O
loop    O
diuretic    O
agent    O
that    O
was    O
brought    O
to    O
market    O
in    O
1981    O
by    O
Boehringer    O
Mannheim    O
.    O


